See more : Zhejiang Jinsheng New Materials Co.,Ltd. (300849.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Embecta Corp. (EMBC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Embecta Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Bangkok Bank Public Company Limited (BKKLY) Income Statement Analysis – Financial Results
- Vor Biopharma Inc. (VOR) Income Statement Analysis – Financial Results
- Unique Mining Services Public Company Limited (UMS.BK) Income Statement Analysis – Financial Results
- Mohammed Hasan AlNaqool Sons Co. (9514.SR) Income Statement Analysis – Financial Results
- Centricus Acquisition Corp. (CENHW) Income Statement Analysis – Financial Results
Embecta Corp. (EMBC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.embecta.com
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Cost of Revenue | 387.90M | 370.90M | 354.60M | 365.00M | 322.90M | 323.00M |
| Gross Profit | 735.20M | 749.90M | 774.90M | 800.00M | 762.60M | 786.00M |
| Gross Profit Ratio | 65.46% | 66.91% | 68.61% | 68.67% | 70.25% | 70.87% |
| Research & Development | 78.80M | 85.20M | 66.90M | 63.00M | 61.40M | 62.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 240.00M | 215.00M | 222.00M |
| SG&A | 365.10M | 341.30M | 294.80M | 240.00M | 214.70M | 222.00M |
| Other Expenses | 124.50M | 101.90M | 44.70M | 5.00M | -700.00K | -2.00M |
| Operating Expenses | 568.40M | 528.40M | 406.40M | 308.00M | 276.10M | 284.00M |
| Cost & Expenses | 956.30M | 899.30M | 761.00M | 673.00M | 599.00M | 607.00M |
| Interest Income | 0.00 | 0.00 | 46.20M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 112.30M | 107.00M | 46.20M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.20M | 32.60M | 31.70M | 38.00M | 38.00M | 36.00M |
| EBITDA | 199.00M | 245.40M | 400.20M | 530.00M | 524.00M | 538.00M |
| EBITDA Ratio | 17.72% | 21.90% | 34.83% | 45.49% | 48.28% | 48.51% |
| Operating Income | 166.80M | 221.50M | 309.60M | 492.00M | 486.50M | 502.00M |
| Operating Income Ratio | 14.85% | 19.76% | 27.41% | 42.23% | 44.82% | 45.27% |
| Total Other Income/Expenses | -122.60M | -115.80M | -53.00M | 3.00M | -700.00K | -2.00M |
| Income Before Tax | 44.20M | 105.70M | 256.60M | 495.00M | 485.80M | 500.00M |
| Income Before Tax Ratio | 3.94% | 9.43% | 22.72% | 42.49% | 44.75% | 45.09% |
| Income Tax Expense | -34.10M | 35.30M | 33.00M | 80.00M | 58.20M | 68.00M |
| Net Income | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| Net Income Ratio | 6.97% | 6.28% | 19.80% | 35.61% | 39.39% | 38.95% |
| EPS | 1.36 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| EPS Diluted | 1.34 | 1.22 | 3.92 | 7.31 | 7.50 | 7.58 |
| Weighted Avg Shares Out | 0.00 | 57.24M | 57.06M | 56.80M | 57.00M | 57.00M |
| Weighted Avg Shares Out (Dil) | 0.00 | 57.76M | 57.06M | 56.80M | 57.00M | 57.00M |
Embecta Corp's (EMBC) CEO Dev Kurdikar on Q3 2022 Results - Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q3 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Pravesh Khandelwal – Head-Investor Relations Dev Kurdikar – Chief Executive Officer Jake Elguicze – Chief Financial Officer Conference Call Participants Travis Steed –...
embecta Announces Earnings Conference Call Information for the Third Quarter of Fiscal Year 2022
PARSIPPANY, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that...
Spinoffs Roundup: These Companies Could Unlock Value in 2022
Spinoffs are known for being a mixed bag from the investor's viewpoint. Some of them can unlock the true value of businesses by allowing them to focus on their niches rather than being hampered by underinvestment and undervaluation as part...
Embecta Is A Winner In A Growing Market
Embecta has a history of profitability, a strong base of revenues, and good free cash flow generation. Diabetes is a large market whose patients are obliged to use insulin for the rest of their lives. This provides a lot of...
Embecta Corp. (EMBC) CEO Devdatt Kurdikar on Q2 2022 Results - Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q2 2022 Results Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Devdatt Kurdikar - President and Chief Executive Officer Jake Elguicze - Senior Vice President and Chief Financial Officer Conference Call Participants Marie...
Why Embecta Shares Are Falling Today
Becton Dickinson and Co's (NYSE: BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ: EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis, down 1.3% on a constant currency basis. Of the decrease, $6.0 million was attributable to unfavorable.
Medliminal’s New Advocacy Program Revolutionizes Medical Bill Review
MANASSAS, Va.--(BUSINESS WIRE)--Medliminal, LLC announced today the public launch of its trailblazing Employee Medical Bill Champion (EMBC) program. EMBC is a medical bill compliance solution designed to protect employees from overpaying on medical bills. In normal conditions, over 90% of...
IEEE Announces IT Healthcare Standard and New Projects in Advance of the IEEE Annual International Conference of the Engineering in Medicine and Biology Society (EMBC ’17)
PISCATAWAY, N.J.--(BUSINESS WIRE)--IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE-SA), today announced the availability of IEEE 11073-20702™—Health informatics: Point-of-Care Medical Device Communication—Standard for Medical Devices Communication Profile for Web...
CORRECTING and REPLACING IEEE Approves Standard Revision to Enable Open Communication and Interoperability for Glucose Metering Devices
PISCATAWAY, N.J.--(BUSINESS WIRE)--Fourth paragraph of release should read: The IEEE 11073-10417 standard, in conjunction with IEEE 11073-10425™ and IEEE 11073-10419™, enables a toolbox for supporting diabetes patients and establishes a solid foundation for accelerating research in the domain of artificial...
Source: https://incomestatements.info
Category: Stock Reports